The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.


Targeting key intracellular signals to reduce inflammation2

  • Through intracellular PDE4 inhibition, OTEZLA reduces production of pro-inflammatory mediators and boosts production of anti-inflammatory mediators2
  • These mediators are implicated in the pathogenesis of psoriasis and psoriatic arthritis1,2

OTEZLA has broad effects on the cytokines involved in multiple manifestations of psoriatic arthritis1

Inflammatory state, which involves pro-inflammatory mediators and anti-inflammatory mediators
Cross-section of human cell that illustrates OTEZLA® preventing the hydrolysis of cAMP to AMP
Representation of the increase in anti-inflammatory mediators, such as IL-10, and the decrease of pro-inflammatory mediators, such as IL-17

PDE4 is a key inflammatory mediator

  • PDE4 is active in immune cells, keratinocytes, and synovial cells
  • PDE4 converts cAMP to AMP, which increases inflammatory signaling

OTEZLA is an oral PDE4 inhibitor

  • Blocking PDE4 maintains intracellular cAMP levels higher than AMP
  • Higher levels of cAMP help lead to balanced immune signaling

Blocking PDE4 helps regulate immune signaling

  • Decreased production of pro-inflammatory mediators
  • Increased production of anti-inflammatory mediators
Phosphodiesterase 4 Phosphodiesterase 4
Adenosine monophosphate Adenosine monophosphate
Cyclic adenosine monophosphate Cyclic adenosine monophosphate

Impact of OTEZLA on production of selected cytokines3

OTEZLA® reduces production of some pro-inflammatory cytokines and increases production of other anti-inflammatory cytokines


Watch the video
  1. OTEZLA Summary of Product Characteristics. Amgen Europe B.V. Minervum 7061, 4817 ZK Breda, The Netherlands; 2020.
  2. Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26(9):2016-2029.
  3. Schafer PH, Chen P, Fang L, et al. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1). J Immunol Res. 2015;2015(1):1-10.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.